title: HLA-B*1502 allele is associated with a cross-reactivity pattern of cutaneous adverse reactions to antiepileptic drugs.
abstract: The US Food and Drug Administration has recommended genetic screening for the human leucocyte antigen-B (HLA-B)*1502 allele in patients of Asian ethnicity before starting carbamazepine therapy, to avoid the fatal adverse treatment-related events associated with this drug.  The association between cross-reactivity to antiepileptic drugs (AEDs) and the HLA-B*1502 allele has been only rarely reported. Here, two cases of cross-reactivity to AEDs, where cutaneous adverse drug reactions (cADRs) developed in female Han Chinese patients with epilepsy who tested  positive for the HLA-B*1502 allele, are described. If the genetic association could be confirmed in larger studies, the HLA-B*1502 allele should be tested for in any patient experiencing cADRs, to avoid crossreactivity to AEDs.
authors.affiliation: Department of Neurology, Institute of Neurology, State Key Laboratory of Medical Neurobiology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
authors.forename: J
authors.initials: J
authors.lastname: Wang
authors.forename: J
authors.initials: J
authors.lastname: Zhang
authors.forename: X
authors.initials: X
authors.lastname: Wu
authors.forename: P
authors.initials: P
authors.lastname: Yu
authors.forename: Z
authors.initials: Z
authors.lastname: Hong
mesh_terms: D000293:Adolescent; D000368:Aged; D000483:Alleles; D000927:Anticonvulsants / Q000009:adverse effects*; D003429:Cross Reactions / Q000235:genetics* / Q000276:immunology*; D005260:Female; D056726:Genetic Association Studies; D020022:Genetic Predisposition to Disease; D059910:HLA-B15 Antigen / Q000235:genetics*; D006801:Humans; D008875:Middle Aged; D012867:Skin / Q000187:drug effects / Q000276:immunology*; D055815:Young Adult
chemical_list: D000927:Anticonvulsants; C483536:HLA-B*15:02 antigen; D059910:HLA-B15 Antigen